



From: Doug.Fenwick [mailto:Doug.Fenwick]
Sent: Thursday, September 19, 2013 07:41 PM Eastern Standard Time
To: [redacted]
Cc: Michael.Carland <Michael.Carland>; Michelle.Richens
<Michelle.Richens>; Robert.Spence
<Robert.Spence>; [redacted]
Subject: Re: Urgent TGA inquiry - information on the [redacted] site [SEC=UNCLASSIFIED]

Hi [redacted]

I would really appreciate an early response on this, even if partial.

Thanks

Regards

Doug Fenwick B. Pharm, MBA
Head of Office (Acting)
Office of Manufacturing Quality
Therapeutic Goods Administration
Department of Health and Ageing

Phone: 02 9865 9304
Fax: 02 6203 1526
Email: doug.fenwick [redacted]

Therapeutic Goods Administration
PO Box 100
Woden ACT 2606
www.tga.gov.au

From August 2012, the Office of Manufacturing Quality is using the term 'inspect' instead of 'audit' to describe its core regulatory activities.



From: Robert Spence/TGA/Health
To: [REDACTED]
Cc: Doug Fenwick/TGA/Health [REDACTED] Michael Carland/TGA/Health [REDACTED] Michelle Richens/TGA/Health [REDACTED]
Date: 19/09/2013 10:16 AM
Subject: Urgent TGA inquiry - information on the [REDACTED] site [SEC=UNCLASSIFIED]

Dear FDA Colleagues

I am an associate of both Doug Fenwick and Anton Norder holding the position in TGA's Office of Manufacturing Quality of Projects and Planning Officer. In that capacity, I need to follow up on the media release at

[REDACTED] and [REDACTED] outlining concerns with [REDACTED].

To allow us to better understand the situation with [REDACTED] and address some of the queries we are receiving, could I ask for a response on the following points as a urgent matter:

1. We have two [REDACTED] manufacturing sites on the TGA books that reference the [REDACTED] suburb. I need to firstly confirm that the location of the site in question is [REDACTED]. Please confirm that this is correct site address. Of course our strategy for dealing with the matter centres on having the correct site in the cross hairs.

[REDACTED]

Please contact me immediately if any points above need clarification or additional information.

Any information provided by your agency will be retained in confidence, in accordance with the cooperation arrangements and confidentiality undertakings exchanged between the TGA and the US FDA. The material is confidential non-public information and will not be disclosed to third parties without your agency's prior written agreement.

Thank you in advance.

Rob Spence
Projects and Planning Officer
Office of Manufacturing Quality

Phone: 02 6232 8752
email: robert.spence [REDACTED]

Therapeutic Goods Administration
Department of Health and Ageing

PO Box 100
Woden ACT 2606

www.tga.gov.au

